Glial Fibrillary Acidic Protein as a Potential Indicator for Symptomatic Intracranial Hemorrhage in Acute Ischemic Patients Undergoing Endovascular Thrombectomy
Minghao Li,Hua Liu,Mingyang Xu,Baiyang Yu,Minwang Guo,Xiaorong Wang,Guomei Shi,Rujuan Zhou
DOI: https://doi.org/10.2147/cia.s448180
IF: 3.829
2024-01-23
Clinical Interventions in Aging
Abstract:Minghao Li, 1, 2, &ast Hua Liu, 1, 3, &ast Mingyang Xu, 1, 3 Baiyang Yu, 3, 4 Minwang Guo, 1, 3 Xiaorong Wang, 1, 3 Guomei Shi, 1, 3 Rujuan Zhou 1, 3 1 Stroke Center, Taixing People's Hospital, Taixing, Jiangsu, People's Republic of China; 2 Department of Vascular Surgery, Taixing People's Hospital, Taixing, Jiangsu, People's Republic of China; 3 Department of Neurology, Taixing People's Hospital, Taixing, Jiangsu, People's Republic of China; 4 Department of Neurology, Taixing Clinical College of Bengbu Medical College, Bengbu, Anhui, People's Republic of China &astThese authors contributed equally to this work Correspondence: Guomei Shi; Rujuan Zhou, Stroke Center, Taixing People's Hospital, No. 1 Changzheng Road, Taixing, Jiangsu Province, 225400, People's Republic of China, Tel +86-15240200702 ; +86-13951158499, Email ; Background: The correlation between glial fibrillary acidic protein (GFAP) and symptomatic intracranial hemorrhage (sICH) in acute ischemic stroke (AIS) patients undergoing endovascular thrombectomy (EVT) treatment remains uncertain. We aimed to assess the association between levels of GFAP in the bloodstream and the occurrence of sICH. Methods: Between June 2019 and May 2023, 142 consecutive AIS patients undergoing EVT at Stroke Center and 35 controls from the Physical Examination Center were retrospectively included. The levels of GFAP in the bloodstream were quantified using enzyme-linked immunosorbent assay prior to endovascular treatment (T1) and 24 h after the procedure (T2). The identification of sICH was based on the Heidelberg Bleeding Classification. Results: Serum GFAP levels at T1 in AIS patients were significantly higher than those in the controls (0.249 [0.150– 0.576] versus 0.065 [0.041– 0.110] ng/mL, p = 0.001), and there was a notably elevation in GFAP levels at T2 compared to T1 (3.813 [1.474, 5.876] versus 0.249 [0.150– 0.576] ng/mL, p = 0.001). Of the 142 AIS patients, 18 (14.5%) had sICH after EVT. Serum GFAP levels at T2 showed significant associations with sICH in both the unadjusted model (OR 1.513, 95% CI 1.269– 1.805, p = 0.001) and multivariable adjusted model (OR 1.518, 95% CI 1.153– 2.000, p = 0.003). Furthermore, the addition of GFAP at T2 to conventional model resulted in a significant enhancement of risk reclassification for sICH (integrated discrimination improvement [IDI] 0.183, 95% CI 0.070– 0.295, p = 0.001). Conclusion: Serum GFAP levels were notably increased in AIS patients 24 h after EVT. Elevated GFAP levels were correlated to an elevated risk of sICH. GFAP could potentially serve as a dependable indicator for sICH in AIS individuals who treated with EVT. Keywords: glial fibrillary acidic protein, stroke, symptomatic intracranial hemorrhage, indicator, endovascular thrombectomy Stroke has been identified as a standout cause of both mortality and morbidity in China, and it also contributes significantly to healthcare expenses. 1,2 The implementation of endovascular thrombectomy (EVT) has led to notable enhancements in clinical outcomes for acute ischemic stroke (AIS) patients involving occlusion of large vessels. 3,4 Symptomatic intracranial hemorrhage (sICH) is a highly concerning complication following interventional procedures among AIS individuals, with reported incidence rates ranging from 4.4% to 16.0%. 3,5 Previous studies have consistently demonstrated that sICH is associated with an elevated risk of unfavorable clinical outcomes and a diminished benefit-to-risk ratio of EVT accordingly. 6–8 Hence, timely and precise identification of sICH following EVT holds importance for enhancing perioperative management and clinical prognosis. Neuroinflammation is a pervasive phenomenon in the pathological progression of brain ischemic. 9 Astrogliosis, a pivotal aspect of neuroinflammation, is distinguished by the substantial elevation of glial fibrillary acidic protein (GFAP) expression. The excessive expression of GFAP has been documented in diverse neurological disorders, including dementia, autoimmune encephalitis, multiple sclerosis (MS), traumatic brain injury, and malignant brain tumors. 10–14 Recently, GFAP has been proposed as a reliable biomarker for distinguishing AIS from intracerebral hemorrhage. 15,16 Moreover, elevated GFAP levels were intimately related to unfavorable prognosis at 90 days in patients after EVT for large vessel occlusion. 17 Furthermore, patients with higher GFAP levels at 24 -Abstract Truncated-
geriatrics & gerontology,gerontology